Oracle stock in focus for Monday after Morgan Stanley target cut flags AI buildout costs

Oracle stock in focus for Monday after Morgan Stanley target cut flags AI buildout costs

New York, Jan 25, 2026, 10:33 EST — The market has closed.

Oracle shares slipped 0.6% on Friday, finishing at $177.16. The drop followed a price target cut from Morgan Stanley, which cautioned that investors might be underestimating the expenses tied to the company’s push to ramp up AI data-center capacity. 1

The call hit a shaky tape for big tech, with investors increasingly distinguishing “AI demand” from actual “AI profits.” Oracle stands out in this trade, locking in hefty cloud deals—but it still requires hardware, power, and real estate to fulfill those commitments.

Tension is high this week. The Federal Reserve convenes Jan. 27-28, while earnings reports roll in from Microsoft, Meta, Tesla, and Apple. These results could shift sentiment on cloud spending and capital intensity throughout the sector. 2

Morgan Stanley’s Keith Weiss highlighted the “significant capital intensity” of the infrastructure buildout and lowered his price target to $213 from $320. He maintained an equal-weight rating, according to Barron’s. 1

Oracle’s recent earnings highlighted the vast scope investors are grappling with. Remaining performance obligations—contracted work still off the books—hit $523 billion, soaring 438% year over year. Finance chief Doug Kehring noted the quarter brought in fresh commitments “from Meta, NVIDIA, and others.” 3

January has seen sharp swings in Oracle’s stock. By Friday, shares ended roughly 7% lower than their close on Jan. 16, following a selloff that pushed the price below $180 mid-month. 4

Oracle handed out a quarterly cash dividend of 50 cents per share on Jan. 23, according to a previous filing — highlighting how shareholder returns are now balancing against an expanding spending cycle. 5

A potential pitfall for bulls is that the contracts might have slimmer margins than anticipated, or that capacity grows quicker than customer demand, forcing the company to shoulder costs before seeing any revenue. Rising financing expenses would only make that balance riskier.

Oracle’s message to customers is straightforward: it has the supply, can ramp up fast, and supports workloads across multiple clouds. If demand stays steady, investors might tolerate short-term hits to free cash flow.

On Monday, traders will keep an eye on whether the stock can hold above last week’s lows and if tech sentiment remains steady following a volatile Friday that saw major U.S. indexes end largely flat. 6

After the Fed’s January 28 decision, the spotlight shifts to Oracle’s fiscal third-quarter earnings, slated for mid-March according to its investor-relations FAQ. 7

Stock Market Today

MARA stock jumps 22% into weekend as bitcoin whipsaws; Monday risk test looms

MARA stock jumps 22% into weekend as bitcoin whipsaws; Monday risk test looms

7 February 2026
MARA shares jumped 22.4% to $8.24 Friday, trading higher after hours, as the company moved $87 million in bitcoin to major custodians. About 82.4 million MARA shares changed hands. Bitcoin hovered near $68,928 Saturday. A MARA filing showed its general counsel had shares withheld for taxes on vested stock units, not an open market sale.
Apple stock (AAPL) set for Monday test as memory-chip crunch revives iPhone price question

Apple stock (AAPL) set for Monday test as memory-chip crunch revives iPhone price question

7 February 2026
Apple shares closed up 0.8% at $278.12 Friday, then slipped 0.3% after hours. A global DRAM shortage is raising component costs, putting pressure on Apple’s pricing ahead of its Feb. 24 shareholder meeting. CEO Tim Cook said memory prices will rise “sharply” but gave no details on possible iPhone price hikes. Investors await signals before next week’s U.S. inflation data.
Roivant stock surges on brepocitinib skin-disease data; what to watch into Monday

Roivant stock surges on brepocitinib skin-disease data; what to watch into Monday

7 February 2026
Roivant shares surged 22.4% to $25.82 after Phase 2 data showed its drug brepocitinib outperformed placebo in cutaneous sarcoidosis, with no serious adverse events. The company plans a Phase 3 trial in 2026 and has filed for FDA approval in dermatomyositis. Quarterly revenue reached $2 million, with a $313.7 million loss. Cash holdings stood at $4.5 billion.
Samsung Electronics stock price: Why 005930 heads into earnings week with 200,000-won targets back on the table
Previous Story

Samsung Electronics stock price: Why 005930 heads into earnings week with 200,000-won targets back on the table

Tencent stock price: Nvidia H200 chip orders loom as 0700.HK heads into Monday
Next Story

Tencent stock price: Nvidia H200 chip orders loom as 0700.HK heads into Monday

Go toTop